Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

CD133 expression associated with poor prognosis in ovarian cancer.

Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J.

Mod Pathol. 2012 Mar;25(3):456-64. doi: 10.1038/modpathol.2011.170. Epub 2011 Nov 11.

2.

Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.

Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, Xia R, Chen S, Deng A.

Neoplasma. 2012;59(3):310-5. doi: 10.4149/neo_2012_040.

PMID:
22296500
3.

Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.

Stemberger-Papić S, Vrdoljak-Mozetic D, Ostojić DV, Rubesa-Mihaljević R, Krigtofić I, Brncić-Fisher A, Kragević M, Eminović S.

Coll Antropol. 2015 Sep;39(3):745-53.

PMID:
26898076
4.

Expression of CD133-1 and CD133-2 in ovarian cancer.

Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G.

Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14. Epub 2007 Sep 13.

PMID:
17868344
5.

Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma.

Yu L, Zhou L, Wu S, Gong X, Feng Z, Ma L, Zhu B, Yao N, Wang D, Dong H.

World J Surg Oncol. 2014 Apr 24;12:118. doi: 10.1186/1477-7819-12-118.

6.

Significance of CD133 expression in esophageal squamous cell carcinoma.

Okamoto H, Fujishima F, Nakamura Y, Zuguchi M, Ozawa Y, Takahashi Y, Miyata G, Kamei T, Nakano T, Taniyama Y, Teshima J, Watanabe M, Sato A, Ohuchi N, Sasano H.

World J Surg Oncol. 2013 Mar 1;11:51. doi: 10.1186/1477-7819-11-51.

7.
8.

Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.

Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K.

Int J Clin Pract. 2008 Aug;62(8):1212-8. doi: 10.1111/j.1742-1241.2008.01777.x. Epub 2008 May 8.

PMID:
18479363
9.

CD133 expression predicts for non-response to chemotherapy in colorectal cancer.

Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M.

Mod Pathol. 2010 Mar;23(3):450-7. doi: 10.1038/modpathol.2009.181. Epub 2010 Jan 15.

10.

Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.

Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J.

Histopathology. 2009 Sep;55(3):284-93. doi: 10.1111/j.1365-2559.2009.03378.x.

PMID:
19723143
11.

Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.

Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, Barresi V, Scannone D, Danese S, Cittadini A, Sgambato A.

Scand J Gastroenterol. 2012 Oct;47(10):1211-7. Epub 2012 Aug 3.

PMID:
22856425
12.

Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer.

Liang J, Yang B, Cao Q, Wu X.

Gynecol Obstet Invest. 2016;81(6):529-536. Epub 2016 Apr 29.

PMID:
27160772
13.

Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma.

Zhang J, Chang DY, Mercado-Uribe I, Liu J.

Hum Pathol. 2012 Sep;43(9):1405-12. doi: 10.1016/j.humpath.2011.10.016. Epub 2012 Mar 7.

14.

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.

Zhao P, Lu Y, Jiang X, Li X.

Cancer Sci. 2011 May;102(5):1107-11. doi: 10.1111/j.1349-7006.2011.01894.x. Epub 2011 Feb 28.

15.

Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.

Sprenger T, Conradi LC, Beissbarth T, Ermert H, Homayounfar K, Middel P, Rüschoff J, Wolff HA, Schüler P, Ghadimi BM, Rödel C, Becker H, Rödel F, Liersch T.

Cancer. 2013 Jan 1;119(1):26-35. doi: 10.1002/cncr.27703. Epub 2012 Jun 26.

16.

AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Yang F, Guo X, Yang G, Rosen DG, Liu J.

Mod Pathol. 2011 Jun;24(6):836-45. doi: 10.1038/modpathol.2011.44. Epub 2011 Mar 25.

17.

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ.

Cancer Res. 2011 Jun 1;71(11):3991-4001. doi: 10.1158/0008-5472.CAN-10-3175. Epub 2011 Apr 15.

18.

CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.

Costa WH, Rocha RM, Cunha IW, Fonseca FP, Guimaraes GC, Zequi Sde C.

World J Urol. 2012 Aug;30(4):553-8. doi: 10.1007/s00345-011-0769-x. Epub 2011 Oct 4.

PMID:
21969131
19.

Prognostic value of CD133 expression in stage I lung adenocarcinomas.

Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M.

Int J Clin Exp Pathol. 2010 Dec 4;4(1):32-42.

20.

DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.

Kim KH, Kang YJ, Jo JO, Ock MS, Moon SH, Suh DS, Yoon MS, Park ES, Jeong N, Eo WK, Kim HY, Cha HJ.

Biochem Biophys Res Commun. 2014 May 2;447(2):315-22. doi: 10.1016/j.bbrc.2014.03.144. Epub 2014 Apr 13.

PMID:
24727449

Supplemental Content

Support Center